
July 1 (Reuters) - BioXcel Therapeutics Inc BTAI.O:
BIOXCEL THERAPEUTICS RECEIVES SECOND POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) TO CONTINUE SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA
BIOXCEL THERAPEUTICS INC - TOPLINE DATA FOR SERENITY AT-HOME TRIAL EXPECTED IN Q3 2025
BIOXCEL THERAPEUTICS INC - DSMB RECOMMENDS CONTINUATION OF SERENITY AT-HOME TRIAL